Investigational drug · Phase 2
AB680
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Metastatic Colorectal Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 20, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
11
Any phase or sponsor naming "AB680"
First trial start
2021
May 10, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AB680", any sponsor or status.
Conditions studied
As listed on its trial records.
- Metastatic Colorectal Cancer
Approved drugs for the same conditions: Colorectal cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "AB680" as an intervention, largest first.
- An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.Pivotal-lookingCompleted
Arcus Biosciences, Inc.Industry
NCT04660812 · 227 participants · Start May 10, 2021 · Primary completion Sep 5, 2025
Drug: AB680; Etrumadenant and 4 more · For: Metastatic Colorectal Cancer
Sites: Tucson, Arizona; Duarte, California; Santa Monica, California · 44 sites in all
- A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal MalignanciesPivotal-lookingCompleted
Arcus Biosciences, Inc.Industry
NCT04104672 · 196 participants · Start Nov 6, 2019 · Primary completion Jul 21, 2026
Drug: AB680; Zimberelimab and 2 more · For: Advanced Pancreatic Cancer
Sites: Santa Monica, California; St Louis, Missouri; New York, New York · 9 sites in all
- Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate CancerPivotal-lookingCompleted
Arcus Biosciences, Inc.Industry
NCT04381832 · 173 participants · Start Jul 7, 2020 · Primary completion Aug 30, 2024
Drug: Etrumadenant; Zimberelimab and 4 more · For: Prostatic Neoplasms, Castration-Resistant; Androgen-Resistant Prostatic Neoplasms; Castration Resistant Prostatic Neoplasms and 1 more
Sites: Cerritos, California; Encino, California; Orange, California · 19 sites in all
Jonsson Comprehensive Cancer CenterAcademic, hospital or other
NCT05688215 · 141 participants (planned) · Start Mar 7, 2023 · Primary completion Dec 31, 2027
Drug: Fluorouracil; Irinotecan and 5 more · For: Borderline Resectable Pancreatic Adenocarcinoma; Locally Advanced Pancreatic Ductal Adenocarcinoma
Sites: Los Angeles, California
Arcus Biosciences, Inc.Industry
NCT03677973 · 64 participants · Start Oct 16, 2018 · Primary completion Aug 19, 2019
Drug: AB680 · For: Healthy Volunteers
Sites: Melbourne, Australia
Gulam ManjiAcademic, hospital or other
NCT06048484 · 60 participants (planned) · Start May 10, 2024 · Primary completion Apr 2027
Drug: Zimberelimab; Quemliclustat and 2 more · For: Pancreatic Ductal Adenocarcinoma
Sites: Lake Success, New York; New York, New York; Chapel Hill, North Carolina · 5 sites in all
- Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)Active, not recruiting
Nataliya UbohaAcademic, hospital or other
NCT06048133 · 33 participants (planned) · Start Mar 8, 2024 · Primary completion Dec 2026
Drug: Gemcitabine; Cisplatin and 2 more · For: Biliary Tract Carcinoma; Cholangiocarcinoma; Bile Duct Cancer
Sites: Indianapolis, Indiana; Ann Arbor, Michigan; New Brunswick, New Jersey · 4 sites in all
Arcus Biosciences, Inc.Industry
NCT04575311 · 32 participants · Start Oct 20, 2020 · Primary completion Sep 22, 2021
Drug: AB680 · For: Healthy Volunteers
Sites: Melbourne, Australia
Fred Hutchinson Cancer CenterAcademic, hospital or other
NCT07667335 · 27 participants (planned) · Start Oct 20, 2026 · Primary completion Jul 16, 2029
Drug: Quemliclustat; Enfortumab Vedotin and 1 more · For: Locally Advanced Bladder Urothelial Carcinoma; Locally Advanced Renal Pelvis Urothelial Carcinoma; Locally Advanced Ureter Urothelial Carcinoma and 10 more
Sites: Seattle, Washington
Catherine SpinaAcademic, hospital or other
NCT05915442 · 23 participants (planned) · Start Jul 1, 2023 · Primary completion Dec 1, 2026
Drug: Quemliclustat; Etrumadenant and 1 more · For: Oligometastatic Prostate Cancer
Sites: New York, New York
Newest research
PubMed records naming it or its code names, newest first.
- Celastrol Ameliorates Systemic Lupus Erythematosus via Restoring Nt5e/ adenosine-dependent Th17/Treg Balance.
Jiang Z, Li S, Li Y, et al. · Phytomedicine 2026
- Potent Competitive Inhibitors of Ecto-5'-nucleotidase (CD73) based on 6ߛ(Het)aryl-7-deazapurine Ribonucleoside 5'ߛOߛBisphosphonates.
inkevičiuıtu U, ímová M, Staník R, et al. · ACS Pharmacol Transl Sci 2026
- Overcoming EGFR-Mediated Dendritic Cell Dysfunction to Enhance Anti-tumor Immunity in EGFR-Mutant NSCLC by Precisely Targeting CD73 With pH-responsive Nanocarriers.
Shang X, Geng X, Wang Z, et al. · Adv Sci (Weinh) 2026
- CD73 inhibitor AB680 suppresses glioblastoma in mice by inhibiting purine metabolism and promoting P2RY12+ microglia transformation.
Gao PP, Jiang HF, Du YW, et al. · Acta Pharmacol Sin 2025
- The interaction of AB-680, a CD73 inhibitor, with NBTI, a nucleoside transporter inhibitor, on the adenosinergic control of atrial contractility.
Ovari I, Brezniczky AB, Laczovics A, et al. · Front Pharmacol 2025
- Identification and Analysis of Anticancer Therapeutic Targets from the Polysaccharide Krestin (PSK) and Polysaccharopeptide (PSP) Using Inverse Docking.
López-Gil CI, Téllez-Jurado A, Velasco-Velázquez MA, et al. · Molecules 2024
Also in development for Metastatic Colorectal Cancer
- Telisotuzumab AdizutecanABBV-400Phase 316 trials
AbbVie · c-MET, Non-Squamous Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer
- AK117Phase 314 trials
Akeso · Advanced Malignant Tumors, ACUTE MYELOID LEUKEMIA; AML, Higher-risk Myelodysplastic Syndromes
- VolrustomigMEDI5752Phase 313 trials
AstraZeneca · Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer
- Anlotinib hydrochlorideAL3818, CatequentenibPhase 312 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Alveolar Soft Part Sarcoma, Metastatic Colorectal Cancer, Endometrial Neoplasms
- PucotenlimabHX008Phase 36 trials
Lepu Biopharma Co., Ltd. · Head and Neck Squamous Cell Carcinoma, Melanoma, Hepatocellular Carcinoma
- CyclophosphamidPhase 33 trials
Alentis Therapeutics AG · Glomerulonephritis Rapidly Progressive, Diffuse Large B-Cell Lymphoma (DLBCL), Metastatic Colorectal Cancer
- CTX-009Phase 32 trials
Compass Therapeutics · Biliary Tract Cancer, Cholangiocarcinoma, Gall Bladder Cancer
- Precemtabart tocentecanPrecem-TcT, M9140Phase 32 trials
EMD Serono Research & Development Institute, Inc. · Metastatic Colorectal Cancer, Solid Tumors, Gastric Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.